{"entity":{"id":"paper-heo-cancerdetect-validation-plos-one-2025","kind":"paper","name":"Analytical validation of a hybrid-approach combining tumor-informed and tumor-agnostic bespoke ctDNA panel assay for the sensitive detection of minimal residual disease","aka":[],"tldr":"The laboratory validation of IMBdx's personalised blood test for leftover cancer, which reached one part in 100,000 on test mixtures.","summary":"CancerDetect (formerly reported as AlphaLiquid Detect) combines personalised (bespoke) mutations with tumour-agnostic actionable hotspot mutations in a hybridisation-capture assay. Its analytical validation reported a limit of detection down to 0.001 per cent (10^-5) with 99.9 per cent specificity.","asOf":"2026-11-04","links":[{"label":"Heo et al., PLoS One 2025","url":"https://doi.org/10.1371/journal.pone.0334282"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/41212866/"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["mrd-testing"],"targets":[],"drugs":["cancerdetect-imbdx"],"companies":["imbdx"],"institutions":[],"pathways":[],"terms":["mrd","ctdna","tumour-informed-assay"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"PLoS One","year":2025,"doi":"10.1371/journal.pone.0334282","pmid":"41212866","authors":"Heo S, Ham SK, Lee H, et al.","paperType":"methods","findings":["Limit of detection 0.001% (10^-5) with 99.9% specificity."],"whatItMeans":"A Korean residual disease test reports a limit at ten parts per million, on germline-variant mixtures rather than tumour plasma.","caveats":["The full text measured the bespoke limit on a 385-SNP cell-line mixture; hotspot regions had a limit of 0.1 per cent."]},"route":"/key-papers/paper-heo-cancerdetect-validation-plos-one-2025/","neighbours":{"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"drug":[{"id":"cancerdetect-imbdx","kind":"drug","name":"CancerDetect","route":"/drugs/cancerdetect-imbdx/"}],"company":[{"id":"imbdx","kind":"company","name":"IMBdx","route":"/companies/imbdx/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"},{"id":"tumour-informed-assay","kind":"term","name":"Tumour-informed versus tumour-naive ctDNA assays","route":"/terms/tumour-informed-assay/"}]}}